PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice

Laurence Klotz, MD, FRCSC; Fred Saad, MD, FRCSC; and the PCPT–MTOPS Consensus Panel

Abstract

Objectives: Two large, recently published, definitive trials evaluated the benefits of 5-alpha reductase inhibitors (5ARIs). The Prostate Cancer Prevention Trial (PCPT) tested the effect of finasteride for prostate cancer prevention and the Medical Therapy of Prostatic Symptoms (MTOPS) study tested its effect in benign prostatic hyperplasia (BPH). Both trials were strongly positive. However, the role of 5ARIs in the clinical management of patients remains controversial. The consensus conference, which forms the basis for this report, attempted to develop an expert opinion, based on these studies, as to the optimal use of 5ARIs in patient management.

Methods: The Canadian Consensus Meeting, organized by the Canadian Urology Research Consortium and the Canadian Urologic Oncology Group, held in Toronto on May 7, 2006, focused on the new data from the PCPT and the MTOPS study. Internationally recognized experts and clinicians discussed the implications of these data on clinical practice and issued a recommendation on the optimal management of patients with BPH.

Results: The Consensus meeting agreed on the following recommendations:
1. The overall results from the PCPT and MTOPS studies are of importance to the urologic, as well as to the greater medical, community.
2. Prostate management guidelines should be updated to include the results from both the MTOPS and the PCPT studies.
3. In the PCPT, the incidence of high-grade cancer was higher in the finasteride-treated group (6.4%), compared with the placebo group (5.1%). Subsequent analyses strongly suggest that this increased prevalence was owing to a detection bias caused by the reduction in prostate volume in patients taking finasteride, compared with patients taking placebo. This resulted in an improved detection at biopsy of high-grade cancer in the finasteride group.
4. In men who have large prostates and lower urinary tract symptoms (LUTS), 5ARIs§ should be considered, both for the treatment of BPH and for prostate cancer risk reduction.
5. For men who are concerned about prostate cancer, it is appropriate to discuss chemoprevention with finasteride.
6. Urologists are encouraged to disseminate these recommendations among other healthcare professionals.

CUAI 2007;1(1):17-21

§Prostate cancer risk reduction has been demonstrated in PCPT with finasteride; however, a class effect with respect to dutasteride has not yet been established.
Some of the data, particularly regarding prostate-specific antigen (PSA) as a surrogate for BPH and prostate cancer risk, and the interpretation of PSA in men on 5ARIs, has been complex. This might have resulted in some reluctance to initiate therapy.

Many primary care physicians are unfamiliar with the data, concerned about missing prostate cancer, suspicious of PSA as a screening test and reluctant to take on a new domain in patient care. Accordingly, the authors believe that a consensus meeting involving experts in the field and including methodologists with a clinical epidemiology background was warranted.

**Methods**

The Canadian Consensus Meeting, organized by the Canadian Urology Research Consortium (CURC) and the Canadian Urologic Oncology Group (CUOG), was held in Toronto on May 7 2006. It focused on the new data from the PCPT and the MTOPS study. Recognized experts and clinicians discussed the implications of these data on clinical practice and issued a recommendation on the optimal management of patients with BPH. Invited presenters reviewed the literature and presented expert opinions. In contrast to formal treatment guidelines, these recommendations are

- focused on specific issues and relevant questions of daily clinical practice;
- meant to be promptly available to the scientific community through a simple and fast development process; and
- representative of a consensus of expert opinions based on published evidence rather than a formal, explicit review of this evidence.

This consensus meeting was held in camera, with representation from prostate cancer and BPH experts in urology academic practice and community practice, as well as clinical epidemiologists and primary care. There were no pharmaceutical company representatives involved in the planning or implementation of the meeting program, nor were they present during the consensus meeting itself (see Acknowledgements).

The key references used by the panel are listed in the References.

**Results**

**PCPT**

The landmark PCPT was the largest completed and published intervention study conducted in the urologic community. It reported, for the first time, that medical intervention reduced the incidence of diagnosed prostate cancer to a clinically meaningful extent. An overview of the findings from the PCPT and the MTOPS study, as well as the following, formed the basis for discussion and consensus development:

- Prostate cancer is one of the leading causes of cancer death in Canada.
- The MTOPS study compared doxazosin, finasteride and the combination with placebo in a large 4-arm study, which showed that in men with prostatic enlargement, the combination of the 2 drugs significantly reduced the risk of urinary retention, surgery for BPH and significant progression of symptoms, compared with either drug alone.
- The PCPT is the largest intervention study ever reported in the urologic community. This study was initiated and funded by the National Cancer Institute of the USA National Institutes of Health. The PCPT reports, for the first time, that medical intervention reduces the incidence of diagnosed prostate cancer to a clinically meaningful extent (level 1B evidence).
- The results showed that finasteride reduced the risk of detecting prostate cancer by 25%, compared with placebo (24.4% placebo v. 18.4% finasteride). The risk was reduced in all subgroups, analyzed by age, ethnicity,
presence of family history and baseline PSA level.

- The finasteride-treated group was found to have a higher proportion of high-grade cancers (6.4%), compared with the placebo group (5.1%) \((p < 0.001)\). Subsequent analyses have concluded, with a high degree of confidence, that this increased prevalence was owing wholly or in great part to a detection bias. This was caused by the following effects:

  1. The reduction in prostate volume in patients taking finasteride, compared with patients taking placebo. The median prostate volume was 24% lower in patients in the finasteride arm, compared with those in the placebo arm (25.5 mL v. 33.6 mL). This resulted in improved detection accuracy at biopsy of high-grade cancer in the finasteride group.

  2. The improved performance of PSA in the finasteride arm, relative to placebo. ROC (receiver operating characteristic) analyses have been conducted on the biomarker PSA. The area under the curve values for placebo and finasteride-treated patients indicated that PSA performed better with respect to overall detection and detection of high-grade cancers in finasteride-treated patients, compared with those receiving placebo. This further biased the study toward the detection of high-grade cancer in the finasteride group.

The increase in high-grade tumours on biopsy was seen within 1 year of finasteride exposure and did not increase over time. Analysis of the radical prostatectomy specimens from the PCPT trial patients has shown no difference in grade, pathologic stage, perineural invasion or any other parameter. An independent report from a large biopsy radical prostatectomy database confirmed that the upgrading rate from biopsy to radical prostatectomy specimen is higher for large volume glands. Taken together, this provides convincing evidence for the artificial nature of the upgrading seen in the PCPT.

The impact of the reduction in incidence of prostate cancer using finasteride has been modelled based on the PCPT. A 24.8% reduction in the incidence of prostate cancer for 5 years among men from the United States, aged 55 years and older would lead to an estimated saving of 316 760 person-years due to finasteride. Allowing for an absolute increase of 6.9% in the proportion of men with high-grade tumours (corresponding to the difference between the rates on the placebo and finasteride arms of the PCPT), the number of person-years saved would be reduced to 262 567. Each absolute increase of 5% in the proportion of patients with high-grade tumours would reduce the number of person-years saved by 39 000. This reinforces the view that the widespread use of finasteride for prevention would have a major impact on population mortality from prostate cancer. In the unlikely event that the high Gleason scores represented an adverse biological effect of finasteride, the detrimental effects of an increased rate of high-grade prostate cancer would still be substantially outweighed by the reduction in overall incidence.

A theoretical limitation of the PCPT data is that prostate cancer mortality was not an end point. This is a characteristic of primary prevention trials in general. There was a consensus that a 25% reduction in the rate of diagnosis, which would result in a significant decrease in the need for treatment and its attendant morbidities and costs, was an important clinical end point. Patients in the trial who were diagnosed with prostate cancer have been treated and will likely be cured. This treatment effect means that it is unlikely that longer-term follow-up will show a difference in prostate cancer mortality.

**MTOPS**

The MTOPS study demonstrated that the combination of finasteride and doxazosin
provided greater benefits than either agent alone. Recent analyses of the MTOPS study indicate that patients with prostates greater than 25 mL may benefit from combination therapy. Similarly, those with a baseline prostate volume greater than 30 mL are at significantly greater risk of progression.

The PCPT also demonstrated the positive effects of finasteride with respect to genitourinary symptoms, with a significantly (p < 0.01) lower incidence of BPH, prostatitis, urinary tract infection for urgency or frequency, urinary retention and transurethral resection of the prostate procedures, compared with patients receiving placebo. These, along with the additional benefit of the reduced risk of developing prostate cancer, have to be balanced against an increase in 5ARI-related side effects, including reduced ejaculate volume, decreased libido and erectile dysfunction.

The use of finasteride to treat men with BPH enhances the use of PSA in detecting prostate cancer. Finasteride decreases PSA by about 50% during the first 12 months of use. As noted above, PSA performs better in detecting prostate cancer in general and high-grade cancer, specifically in men treated with finasteride.

**Consensus Statements**

On the basis of this evidence, we agreed upon the following statements:

1. Implications for LUTS–BPH management:
   a. The 5ARIs finasteride and dutasteride are appropriate and effective treatments for patients with LUTS associated with demonstrable prostatic enlargement (greater than 30 mL). In patients without prostate cancer, a PSA value greater than 1.5 may be a useful marker for prostatic enlargement.
   b. If one assumes a class effect, all combinations of an α1-adrenoceptor antagonist and a 5ARI would be equally effective.
   c. The most robust data supporting the safety and efficacy of the combination used doxazosin and finasteride.
   d. Based on current knowledge, a PSA conversion factor of about 2 for patients taking 5ARIs is required to interpret the test according to accepted cut-off levels. The PSA requires about 6 months to achieve a nadir after 5ARIs are introduced. Further analysis of the PCPT data suggests that finasteride therapy improves the specificity and sensitivity of the PSA test, and enhances detection of high-grade disease.
   e. It is recommended that prostate management guidelines are updated to include the results from these and further studies.

2. Implications for prostate cancer chemoprevention:
   a. The PCPT showed that finasteride significantly reduces the prevalence of histologically proven prostate cancer.
   b. In men who have large prostates and LUTS, 5ARIs§ should be considered, both for treatment of BPH and to reduce prostate cancer risk.
   c. For men who are concerned about prostate cancer, it is appropriate to discuss chemoprevention with finasteride.
   d. In doing the above, it is important to highlight both the benefits and the risks associated with long-term treatment.

3. Implications for patient information:
   a. Physicians should be aware of the findings from the PCPT and the MTOPS study.
   b. Patients treated with 5ARIs for chemoprevention should be monitored for prostate cancer.

4. Implications for the education of the medical community:

§Prostate cancer risk reduction has been demonstrated in PCPT with finasteride; however, a class effect with respect to dutasteride has not yet been established.
a. Urologists are encouraged to disseminate these recommendations among other healthcare professionals, including general practitioners who often play a significant role in the management of BPH–LUTS.
b. Physicians should appropriately counsel their patients about the potential benefits and side effects of treatment with 5ARIs.
c. Management guidelines on prostate disease should be updated to reflect the findings from the PCPT and the MTOPS study.

Conclusions

The MTOPS and the PCPT, 2 of the most important and definitive studies published in the field in the last 5 years, have major implications for the management of men with LUTS–BPH who do, as well as those who do not, have concerns or risk factors for prostate cancer. We achieved a Canadian consensus on the role of 5ARIs in the management of these men. They should be presented with the benefits and the risks of taking a 5ARI and should be assisted in integrating their urinary and sexual symptoms, prostate cancer risk factors and level of concern into their decision-making process.

References


Correspondence: Dr. Laurence Klotz, Division of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Ave., #MG408, Toronto ON M4N 3M5; laurence.klotz@sunnybrook.ca